News | Focused Ultrasound Therapy | March 17, 2021

West Virginia University Addresses Addiction Crisis with Novel Ultrasound Treatment

Rockefeller Neuroscience Institute first-in-the-world to use focused ultrasound to treat opioid use disorder 

WVU Rockefeller Neuroscience Institute staff prepare a patient for a first-in-the-world clinical trial to investigate the use of focused ultrasound technology to treat opioid use disorder. (WVU Photo/Brian Persinger)

WVU Rockefeller Neuroscience Institute staff prepare a patient for a first-in-the-world clinical trial to investigate the use of focused ultrasound technology to treat opioid use disorder. (WVU Photo/Brian Persinger)

March 17, 2021 — On the heels of the country’s deadliest year for drug overdoses, the West Virginia University Rockefeller Neuroscience Institute launched a first-in-the-world clinical trial to investigate the use of focused ultrasound technology to treat those with opioid use disorder. The procedure marks the potential for a new innovative treatment for addiction. 

The goal of the study, conducted in collaboration with Insightec, is to evaluate the safety and potential of focused ultrasound in reducing substance cravings and addictive behaviors. 

During the 30 minute procedure, RNI researchers applied focused ultrasound waves to the nucleus accumbens, a key structure in the brain involved in addiction and anxiety. The research team utilized visuals of drug use and drug paraphernalia to induce cravings prior to and during the procedure. While preliminary, RNI investigators were encouraged by the patient’s positive behavioral response to the focused ultrasound, and plan to further investigate the treatment by enrolling additional patients in the study. 

The study’s first participant, a 39-year-old business owner from West Virginia, is currently enrolled in WVU’s Comprehensive Opioid Addiction Treatment (COAT) program. He has an over 15-year history of substance use disorder, specifically with prescription opioids, heroin and cannabis, and safely and successfully underwent the focused ultrasound procedure in February 2021. 

COVID-19 has tragically intensified our nation’s addiction crisis,” Ali Rezai, M.D., Rockefeller Neuroscience Institute executive chair and principal investigator of this study, said. “We need to explore technological innovations such as focused ultrasound to help patients and families impacted by addiction. At the RNI, we are routinely using focused ultrasound as an FDA-approved procedure to treat tremors and are conducting clinical trials to explore its potential for treating Alzheimer’s disease and brain tumors.” 

Recently released data from the Centers for Disease Control and Prevention show the country’s addiction epidemic worsening during COVID-19. More than 81,000 Americans died from overdose in the 12 months leading up to May 2020, the highest one-year figure in recorded history. 

In addition to focused ultrasound, the WVU team is exploring a range of new technologies to treat addiction that includes deploying the use of wearables and artificial intelligence, transcranial magnetic stimulation and deep brain stimulation. In 2019, the RNI launched a first-in-the-U.S. clinical trial exploring the use of deep brain stimulation to treat addiction, which has helped its first patient celebrate more than a year of sobriety after an 18-year battle with substance use. 

“We were all impressed with the patient’s bravery to help explore new treatment options for substance use disorder. While the current treatment options for substance use disorder work for many, they don’t work for everyone for a variety of reasons,” James Mahoney, Ph.D., RNI addiction researcher, clinical neuropsychologist and assistant professor in the WVU Department of Behavioral Medicine and Psychiatry and Department of Neuroscience, said. “We need to continue exploring new treatments for those struggling with addiction, and I’m hopeful that focused ultrasound technology will provide another tool to assist those in need moving forward.” 

“Clinical research and scientific discovery using the therapeutic power of acoustic energy are helping to transform lives,” Maurice R. Ferré, M.D., Chair and CEO at Insightec commented. “We are excited to continue supporting our partners to pioneer focused ultrasound treatments in the brain for critical diseases like addiction.”

Insightec’s Exablate Neuro uses focused ultrasound guided by magnetic resonance imaging (MRI) technology and is FDA approved to treat tremor from essential tremor and Parkinson’s disease. The company is also working with RNI investigators on first-in-the-U.S. trials of transient opening the blood-brain barrier to treat Alzheimer’s disease, which has shown a reduction in Alzheimer’s plaques in early results

For more information: WVUMedicine/RNI

Related Content

A doctor reading #CXR scans using #SenseCare-Chest #DR Pro #diagnostic #software.

A doctor reading CXR scans using SenseCare-Chest DR Pro diagnostic software.

News | Artificial Intelligence | April 14, 2021
April 14, 2021 — SenseTime, a world-leading...
Comparisons of high definition and standard definition infrared imaging for digital histopathology. Image courtesy of the Beckman Institute

Comparisons of high definition and standard definition infrared imaging for digital histopathology. Image courtesy of the Beckman Institute

News | Breast Imaging | April 14, 2021
April 14, 2021 — Detecting and analyzing breast cancer
A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Image used with permission of RSNA.

A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Read more about this case study. Image used with permission of RSNA.

Feature | Coronavirus (COVID-19) | April 09, 2021 | By Dave Fornell, Editor
While the mass COVID-19 vaccinat
3-D mammography reduces the number of breast cancer cases diagnosed in the period between routine screenings, when compared with traditional mammography, according to a large study from Lund University in Sweden. The results are published in the journal Radiology.

Getty Images

News | Breast Imaging | April 09, 2021
April 9, 2021 — 3-D mammography reduces the number of breast cancer cases diagnosed in the period between routine scr
IV contrast-enhanced 2-mSv 4-mm-thick transverse and coronal (b) CT images show inflamed diverticula (arrows), segmental colonic wall thickening, and adjacent pericolic fat stranding. Image courtesy of the American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

IV contrast-enhanced 2-mSv 4-mm-thick transverse and coronal (b) CT images show inflamed diverticula (arrows), segmental colonic wall thickening, and adjacent pericolic fat stranding. Image courtesy of the American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Computed Tomography (CT) | April 09, 2021
April 9, 2021 — According to an open-acc...
Futuristic campus design of Siemens Healthineers in Bengaluru, India.

Futuristic campus design of Siemens Healthineers in Bengaluru, India.

News | Radiology Business | April 08, 2021
April 8, 2021 — Siemens Healthineers announced t
Axial chest CT examination in a 54-year-old participant. A, On the axial noncontrast chest CT image, the pectoralis muscle (PM) area was segmented and measured in the section above the aortic arch. B, The subcutaneous adipose tissue (SAT) area as the area between the PM and the skin surface on the same section was also measured and the attenuation of pixels in the SAT area was used to determine the individualized threshold for the intermuscular adipose tissue (IMAT). C, The IMAT within the PM was segmented

Axial chest CT examination in a 54-year-old participant. A, On the axial noncontrast chest CT image, the pectoralis muscle (PM) area was segmented and measured in the section above the aortic arch. B, The subcutaneous adipose tissue (SAT) area as the area between the PM and the skin surface on the same section was also measured and the attenuation of pixels in the SAT area was used to determine the individualized threshold for the intermuscular adipose tissue (IMAT). C, The IMAT within the PM was segmented as the areas with Hounsfield units below this threshold for the IMAT (arrowheads). Image courtesy of the Radiological Society of North America

News | Computed Tomography (CT) | April 07, 2021
April 7, 2021 — Body composition information derived from routine chest...
Ultrasound is an invaluable diagnostic tool for the early detection of breast cancer, but the classification of lesions is sometimes challenging and time consuming. Could artificial intelligence hold the answer to solving these problems? Graphic courtesy of Chinese Medical Journal

Ultrasound is an invaluable diagnostic tool for the early detection of breast cancer, but the classification of lesions is sometimes challenging and time consuming. Could artificial intelligence hold the answer to solving these problems? Graphic courtesy of Chinese Medical Journal

News | Artificial Intelligence | April 06, 2021
April 6, 2021 — In 2020, the International Agency for Research on...